How savvy KOL engagement can drive marketing and sales
This article was originally published in Scrip
Executive Summary
A shrewd understanding of how key opinion leadership is changing can help companies drive better launch and marketing campaigns for their drugs. Increasingly strained, localized and patient-centric healthcare systems mean that the days of simply appointing a clinician to write about a drug or present at meetings to raise its profile are gone. To get the help with advocacy and marketing they want, firms must change their strategies and engage with a wider array of KOLs, explains Leyla Hannbeck, head of pharmacy at the National Pharmacy Association.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.